SMART™ clinical study

The SMART™ Total Disc Replacement
Clinical Study
Is this right for you?

Available Clinical Study Sites in the U.S.

The two-level prodisc C Vivo & prodisc C SK clinical study has expanded to multiple sites, each actively enrolling patients in the FDA monitored study. For more information, visit ClinicalTrials.gov (Identifier NCT04012996).


Arizona

Flagstaff, AZ

Investigator: John Hall, MD

Email the Study Coordinator


California

Beverly Hills, CA

Investigators:

  • Todd Lanman, MD
  • Jason Cuellar, MD

Email the Study Coordinator

Los Angeles, CA

Investigators:

  • Brian Perri, MD
  • Neel Anand, MD
  • Patrick Hill, MD
  • Edward Nomoto, MD
  • Khawar Siddique, MD
  • Albert Wong, MD

Email the Study Coordinator

Los Angeles, CA

Investigators:

  • Alexandre Rasouli, MD
  • Ehsan Saadat, MD

Email the Study Coordinator


Colorado

Thornton, CO

Investigator: Michael E. Janssen, DO

Email the Study Coordinator


Florida

Sarasota, FL

Investigator: Ashvin Patel, MD

Email the Study Coordinator

Temple Terrace, FL

Investigators:

  • John Small, MD
  • Steven Tresser, MD

Email the Study Coordinator


Indiana

Carmel, IN

Investigators:

  • Rick Sasso, MD
  • Paul Kraemer, MD
  • Joseph Smucker, MD

Email the Study Coordinator


Kentucky

Paducah, KY

Investigator: Kenneth Strenge, MD

Email the Study Coordinator


Louisiana

Shreveport, LA

Investigators:

  • Pierce Nunley, MD
  • Peter Campbell, MD
  • David Cavanaugh, MD
  • Eubulus Kerr, MD
  • Andrew Utter, MD
  • Rishi Wadhwa, MD

Email the Study Coordinator


Maryland

Baltimore, MD

Investigators:

  • Daniel Gelb, MD
  • Daniel Cavanaugh, MD
  • Eugene Y Koh, MD
  • Steven C Ludwig, MD
  • Charlie Sansur, MD

Email the Study Coordinator


Michigan

Royal Oak, MI

Investigators:

  • Jad Khalil, MD
  • Jeff Fischgrund, MD
  • Mark Jacobson, MD
  • Daniel Park, MD

Email the Study Coordinator


Nevada

Las Vegas, NV

Investigator: Jason Garber, MD

Email the Study Coordinator


New Jersey

Wayne, NJ

Investigators:

  • Michael Faloon, MD
  • Arash Emami, MD
  • Ki Soo Hwang, MD
  • Kumar Sinha, MD

Email the Study Coordinator


New York

New York, NY

Investigators:

  • Aaron J. Buckland, MD
  • John Bendo, MD
  • Jeffrey Goldstein, MD
  • Yong Kim, MD
  • Themistocles Protopsaltis, MD
  • Jeffrey Spivak, MD

Email the Study Coordinator


North Carolina

Charlotte, NC

Investigators:

  • Alden Milam, MD
  • Bruce Darden, MD
  • Eric Laxer, MD
  • Leo Spector, MD

Email the Study Coordinator

Durham, NC

Investigator: David Benjamin Musante, MD

Email the Study Coordinator


Ohio

Solon, OH

Investigators:

  • Robert McLain, MD
  • James S Anderson, MD

Email the Study Coordinator


Pennsylvania

Hershey, PA

Investigators:

  • G. Timothy T. Reiter, MD
  • John Paul Kelleher, MD
  • Michael D. Sather, MD

Email the Study Coordinator


Texas

Fort Worth, TX

Investigator: Jason Tinley, MD

Email the Study Coordinator

Plano, TX

Investigators:

  • Jessica Shellock, MD
  • Scott Blumenthal, MD
  • Richard Guyer, MD
  • Michael Hisey, MD
  • Jack Zigler, MD

Email the Study Coordinator


Utah

Salt Lake City, UT

Investigator: Armen Khachatryan, MD

Email the Study Coordinator


Washington, D.C.

Washington, D.C.

Investigator: Faheem Sandhu, MD

Email the Study Coordinator

 

What should I expect?


What happens before the trial?

Before participating in a study, patients are provided with information about the study and are given the chance to ask questions. This process is called Informed Consent. The purpose of the informed consent process is to make sure patients are adequately informed of important details about the clinical study so they can make an informed choice about their participation. Informed Consent begins before a research volunteer agrees to participate in a trial and continues throughout the study.

The Informed Consent document describes the study to research patients. It includes details about the study’s purpose, length, procedures, risks and benefits, and other information that all patients should know. Patients sign the document before they enter the study, but only after having read and discussed it with the research team and demonstrating an understanding of the information provided. In some cases, there will be multiple Informed Consent documents throughout the study as changes are made to the study protocol or new safety information becomes available. Signing the document(s) and providing consent is not a contract. Patients may withdraw from a study at any time, even if the study is not over.

How am I protected during the trial?

The SMART Study has been reviewed and approved by the FDA. Hospitals and physicians won’t participate until their institutional review board (IRB) has thoroughly reviewed the study protocol and approved it. It is the responsibility of the IRB under federal guidelines to “protect the rights and welfare of research subjects.”

Your rights include:

  1. Ability to ask your physician or Centinel Spine about the study at any time.
  2. Privacy/confidentiality – your research records will be handled as confidentially as is possible within the law.
  3. Ability to withdraw your consent to participate in the study without penalty or loss of benefits at any time.
  4. Compensation for participation will be provided for your time. The ‘informed consent’ document outlines the details of this compensation.
  5. You will be informed of any new risks or findings during the course of the study.

What happens when the trial is over?

All anonymized patient data will be analyzed and submitted to the FDA for review. If the clinical trial is approved, the prodisc C SK and prodisc C Vivo can become available to other surgeons and patients in the U.S. Additionally, the results will be publicly shared on ClinicalTrials.gov, and in appropriate medical journals and with qualified medical professionals.